Our study analyzed PD-L1 expression in 15 tumor samples from three indications (NSCLC, HNSCC or UC) as well as in a large, separate cohort of 200 NSCLC samples, and is the first study of PD-L1 heterogeneity using the VENTANA SP263 assay. Here, CD274 is linked to neoplasm.